KIRKLAND, QC, Sept. 18, 2018 /PRNewswire/ - Valeo Pharma Inc., a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products, and Besins Healthcare, a global pharmaceutical company world leader in novel therapies for gynecology and andrology, today announced a strategic agreement to commercialize Utrogestan® (micronised natural progesterone; 200mg vaginal capsules) in Canada. Utrogestan is indicated for luteal phase support during in-vitro fertilization (IVF) cycles.
Under the terms of the agreement with Besins Healthcare, Valeo Pharma is responsible for all aspects of sales, marketing, quality and distribution activities pertaining to Utrogestan® 200mg vaginal capsules in Canada.
"Besins Healthcare has an international track record of successfully developing, partnering and commercializing Specialty Woman's Health Products," said Steve Saviuk, Chief Executive Officer of Valeo Pharma. "We are excited to add this unique strength of micronized progesterone (Utrogestan® 200mg vaginal capsules) to our Specialty Pharmaceutical portfolio and offer a new choice in a growing area of concern for Canadian families."
"As Utrogestan® has already been granted marketing approval by Health Canada, we are on track for a 2019 product launch," added Marc Leger, Chief Commercial Officer. "Our Specialty pipeline continues to build and we project to launch several new products in Canada over the next 12-18 months."
Antoine Besins, CEO of Besins Healthcare said "We are pleased that Utrogestan is being made available to meet patients' needs in Canada, as in over a hundred countries around the world".
Sunil Sehgal, President, Ascend Therapeutics LLC, a Besins Healthcare company operating in the U.S.A., expressed, "we welcome the opportunity to work closely with Valeo Pharma and look forward to collaborating for a successful launch of Utrogestan in early 2019".
About Valeo Pharma
Valeo Pharma is a specialty pharmaceutical company dedicated to the approval and launch of innovative prescription products in Canada. With a focus on neurodegenerative diseases, woman's health and rare diseases, Valeo Pharma has a growing portfolio of innovative products and a platform to properly manage these products through all stages of commercialization. Headquartered in Kirkland, Quebec, Valeo Pharma has all capabilities internally to register and market health care solutions for Canadian patients. For more information, please visit www.valeopharma.com.
About Besins Healthcare
Besins Healthcare (or the "Company") is a privately owned global pharmaceutical company headquartered in Monaco and operations through over twenty fully-owned affiliated companies around the world, including Ascend Therapeutics LLC. The Company is a world leader in novel therapies for gynecology and andrology. Besins Healthcare, pioneer in transdermal gels, has developed several natural hormone-based therapies over the years including bioavailable natural progesterone for pregnant women and bioavailable natural testosterone for testosterone deficiency syndromes. The Company continue to be a leader in estradiol replacement therapy with the first transdermal gel marketed in Europe. Besins Healthcare products are trusted and prescribed by healthcare professionals in more than 100 countries around the world. For more information, please visit www.besins-healthcare.com.
About Utrogestan®. Utrogestan® 200mg vaginal capsules contains natural micronized progesterone. It is used to assist reproductive techniques ("ART"), such as in-vitro fertilization i.e. gamete intra-Fallopian transfer ("GIFT") or zygote intra-Fallopian transfer ("ZIFT"). Utrogestan® 100 mg oral is used to reduce the symptoms of menopause (change of life). For more information, please visit https://www.besins-healthcare.com/products/#womens.
SOURCE Valeo Pharma inc.